Roche licensed a Chinese biotech's obesity drug in a deal worth up to $1.16 billion
- Chinese: 146 events in the last 90 days
- Previous: earlier the same day · OpenAI's CFO warned businesses that Chinese AI models pose cybersecurity risks
What happened
The Swiss drugmaker will pay up to $100 million upfront to license an RNAi therapy targeting fat tissue from Shanghai-based Rona Therapeutics
Summary assembled by rule from the sources below